Within the Chronic Inflammatory Demyelinating Polyneuropathy Market segment, the market is primarily segmented by Treatment Type into Intravenous Immunoglobulin (IVIg), Corticosteroids, Immunosuppressive Therapy, and Plasmapheresis. IVIg holds a commanding position due to its efficacy and status as a first-line treatment, contributing the largest revenue share. In terms of End-Users, the...